ISSUE 1519
| The full article is available to subscribers | Subscriber Login |
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.
MECHANISM OF ACTION — Dupilumab binds to the IL-4 receptor alpha subunit shared by interleukin (IL)-4 and IL-13 receptors, inhibiting the signaling of these two cytokines, which are thought to be the drivers of atopic dermatitis, asthma, and possibly other allergic diseases.1
STANDARD TREATMENT — Application of moisturizers, emollients, and barrier creams can reduce the need for pharmacologic treatment of atopic dermatitis. Low-potency topical corticosteroids are generally used for treatment of mild atopic dermatitis that fails
... more- M Kraft and M Worm. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol 2017; 13:301.
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- Drugs for allergic disorders. Med Lett Drugs Ther 2017; 59 (in press).
- LA Beck et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130.
- EL Simpson et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335.
- A Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis (AD) with dupilumab and concomitant topical corticosteroids (TCS): a 1-year, randomized, placebo-controlled phase 3 trial (CHRONOS). Presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, Orlando, FL, March 3-7, 2017. Abstract 5267.
- MJ Cork et al. Pharmacokinetics, safety and efficacy of dupilumab in a pediatric population with moderate-to-severe atopic dermatitis: results from an open-label phase 2a trial. Presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, Orlando, FL, March 3-7, 2017. Abstract 5279.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. April 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Immediate Online access to current issue and archives from 1988 to the present
- Mobile access to our mobile site and free apps for iOS, Android and Kindle
- FREE online per issue CME/CE
Article code: 1519b
Electronic, downloadable article - $25
